20/20 GeneSystems, Inc.

Lab-Based Diagnostic Testing Powered by AI and Real-World Data

Claim My Business View on StartEngine
Technology, Healthcare/Medical
Min Investment
Gaithersburg, MD
Offering Date
August 21, 2022
Expected Close Date
November 15, 2022
Amount Raised
Target Raise
No. Investors
Number of Employees
Short Term Debt
Cost of Goods
Long Term Debt
Net Income

Company Description

20/20 GeneSystems develops and commercializes clinical laboratory tests that are improved with machine learning and real-world data. Through our high-complexity CLIA lab, we offer what is believed to be the first multi-cancer screening blood test in the U.S. costing under $200. In response to the global pandemic, we expanded our CLIA laboratory test menu to include PCR testing. Due to our ability to scale our COVID testing operation, 2021 revenues exceeded $9 million with over $1 million in net profits for the year. This represents a more than 300% increase over 2020 revenues. As a result, we ranked no. 131 on the Inc. 5000 list of America’s fastest-growing companies in 2022. To grow our portfolio of tests, the Company has built a Clinical Laboratory Innovation Accelerator, or CLIAx, which we believe is the country’s first accelerator facility for diagnostics start-ups. Our CLIAx is expected to help fuel our product and revenue growth for the next five years and already has two companies signed up to join.


StartEngine OWNERS Exclusive Click here to learn more

$500+ Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

Friends & Family
Invest within the first 2 weeks and receive a 25% increase in the annual interest rate on Convertible Promissory Notes in this Offering, where by the interest rate will increase from 6% to 7.5%.





$500+ Investment
Tier 1
Receive 1/3 off all 20/20 lab tests for 12 months. (Only if available in your country)

$1,000+ Investment
Tier 2
Receive 1/2 off all 20/20 lab tests for 12 months. (Only if available in your country)

$2,500+ Investment
Tier 3
Receive 1/2 off all 20/20 lab tests for 18 months. (Only if available in your country)

$5,000+ Investment
Tier 4
Receive 1/2 off all 20/20 lab tests for 24 months. (Only if available in your country)

$10,000+ Investment
Tier 5
Receive 1/2 off all 20/20 lab tests for life. (Only if available in your country)

Key Deal Facts

One of the first in a fast growing market: 20/20 GeneSystems is one of the first organizations in the white-hot market for multi-cancer early detection (MCED) screening blood tests and is collecting test outcome data from around the world to help us refine and improve our algorithms and remain a market leader. Since the start of 2022 advancing MCEDs has become a priority for  members of Congress and the  U.S. National Cancer Institute.
Experienced Team: Our CEO previously established strategic partnerships with Fortune 500 companies such as Johnson & Johnson, Eastman Kodak, Abbott Diagnostics and Smiths Detection.  Our Board members have built and sold several successful diagnostics and medtech companies.
Investor backing: Our shareholders include China’s Ping An Ventures, likely the world’s largest Healthcare AI company (300 million users of its mobile diagnostic app) & thousands of investors, as well as the Keiretsu Forum, family offices, and over 8,000 crowd investors.

Research Reports

No reports have been submitted

Become a Reporter